Skip to main content

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Haddad, RI; Bischoff, L; Ball, D; Bernet, V; Blomain, E; Busaidy, NL; Campbell, M; Dickson, P; Duh, Q-Y; Ehya, H; Goldner, WS; Guo, T; Yeh, M ...
Published in: J Natl Compr Canc Netw
August 2022

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients. Surgery is also the main treatment for medullary thyroid carcinoma, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable. Anaplastic thyroid carcinoma is almost uniformly lethal, and iodine-131 imaging and radioactive iodine cannot be used. When systemic therapy is indicated, targeted therapy options are preferred. This article describes NCCN recommendations regarding management of medullary thyroid carcinoma and anaplastic thyroid carcinoma, and surgical management of differentiated thyroid carcinoma (papillary, follicular, Hürthle cell carcinoma).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2022

Volume

20

Issue

8

Start / End Page

925 / 951

Location

United States

Related Subject Headings

  • Thyroid Neoplasms
  • Thyroid Carcinoma, Anaplastic
  • Oncology & Carcinogenesis
  • Iodine Radioisotopes
  • Iodine
  • Humans
  • Carcinoma, Neuroendocrine
  • Adenocarcinoma
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., … Darlow, S. (2022). Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(8), 925–951. https://doi.org/10.6004/jnccn.2022.0040
Haddad, Robert I., Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, et al. “Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 20, no. 8 (August 2022): 925–51. https://doi.org/10.6004/jnccn.2022.0040.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Aug;20(8):925–51.
Haddad, Robert I., et al. “Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 20, no. 8, Aug. 2022, pp. 925–51. Pubmed, doi:10.6004/jnccn.2022.0040.
Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh Q-Y, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Aug;20(8):925–951.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

August 2022

Volume

20

Issue

8

Start / End Page

925 / 951

Location

United States

Related Subject Headings

  • Thyroid Neoplasms
  • Thyroid Carcinoma, Anaplastic
  • Oncology & Carcinogenesis
  • Iodine Radioisotopes
  • Iodine
  • Humans
  • Carcinoma, Neuroendocrine
  • Adenocarcinoma
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis